Akeso and Summit Therapeutics’ (SMMT) ivonescimab has cleared another clinical milestone, meeting its overall survival endpoint in the trial that first put the drug on the map.
The PD-1xVEGF bispecific antibody generated enormous excitement roughly two years ago when it delivered a head-to-head progression-free survival win against Merck’s (MRK) Keytruda, one of the best-selling cancer drugs in the world.
That result positioned ivonescimab as perhaps the most credible challenger to Keytruda’s dominance, and it elevated the entire PD-1xVEGF drug class in the eyes of oncology investors and researchers alike.
The new overall survival data from that same trial represents a meaningful step forward, demonstrating that the earlier progression-free survival benefit has now translated into patients living longer.
Despite that achievement, the market and clinical community have responded with considerably more restraint than they showed when the initial progression-free survival results landed.
The measured reception reflects how much the competitive landscape has shifted in the intervening period, with multiple new entrants and data readouts reshaping expectations around the drug class.
Ivonescimab works by simultaneously blocking both PD-1 and VEGF pathways, a dual mechanism that its developers argue can outperform agents targeting either pathway alone.
The original head-to-head win against Keytruda was striking precisely because pembrolizumab remains a standard-of-care backbone across numerous cancer indications globally.
Summit Therapeutics (SMMT) holds rights to develop and commercialise ivonescimab outside of Greater China, giving the company significant exposure to the drug’s commercial potential in Western markets.
Akeso, the Chinese biotech that originated the molecule, retains rights in China and other Asian territories, creating a split development structure that has attracted considerable investor scrutiny.
The overall survival result will now feed into regulatory and commercial discussions, though the tempered reaction suggests analysts are waiting for additional context before revising their outlooks meaningfully.
Whether ivonescimab can ultimately displace or meaningfully compete with Keytruda at a commercial scale remains one of the most closely watched questions in oncology drug development today.